A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety and effectiveness of Stealth liposomal doxorubicin hydrochloride
(DOX-SL) in the long-term treatment of AIDS-related Kaposi's sarcoma (KS) in patients who
previously had good responses to DOX-SL in controlled studies of limited duration, or those
with KS who discontinued treatment with another Kaposi's sarcoma therapy because of
inadequate efficacy or unacceptable toxicity. To provide a defined protocol for Kaposi's
sarcoma patients for whom DOX-SL therapy is indicated.